Last reviewed · How we verify

BE1116 — Competitive Intelligence Brief

BE1116 (BE1116) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant coagulation factor / von Willebrand factor replacement. Area: Hematology.

phase 3 Recombinant coagulation factor / von Willebrand factor replacement von Willebrand factor (VWF) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

BE1116 (BE1116) — CSL Behring. BE1116 is a recombinant human albumin-von Willebrand factor (VWF) fusion protein that replaces or augments deficient VWF function in von Willebrand disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BE1116 TARGET BE1116 CSL Behring phase 3 Recombinant coagulation factor / von Willebrand factor replacement von Willebrand factor (VWF)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant coagulation factor / von Willebrand factor replacement class)

  1. CSL Behring · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BE1116 — Competitive Intelligence Brief. https://druglandscape.com/ci/be1116. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: